RxStrategies, Inc.

Clinical Insights: March 6, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Letybo® (letibotulinumtoxinA-wlbg) Powder for Injection – New Drug Approval – February 29, 2024 – Hugel, a global total medical aesthetics company, announced that the company has received marketing approval…

Read More...

Clinical Insights: February 29, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Amtagvi™ (lifileucel) Suspension for Intravenous Infusion –New Orphan Drug Approval  –February 16, 2024 – The U.S. Food and Drug Administration approved Amtagvi™ (lifileucel), the first cellular therapy indicated for the…

Read More...

Clinical Insights: February 14, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Eohilia™ (budesonide) Oral Suspension – New Drug Approval – February 9, 2024 – Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) has approved Eohilia™ (budesonide oral suspension),…

Read More...

Clinical Insights: February 7, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Yescarta® (axicabtagene ciloleucel) Suspension for Intravenous Infusion – New Label Expansion – January 30, 2024 – Kite, a Gilead Company (Nasdaq: GILD), announced…

Read More...

Clinical Insights: January 24, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Balversa® (erdafitinib) Tablets – New Label Expansion – January 19, 2024 – The Food and Drug Administration approved erdafitinib (Balversa®, Janssen Biotech) for adult patients with locally advanced or metastatic…

Read More...

Connect with RxStrategies at 340B Coalition Winter Conference

The RxStrategies team is thrilled to be attending the upcoming 2024 340B Coalition Winter Conference in San Diego, from January 29th to 31st. We could not agree more that the importance of 340B to the patient care mission has never been greater. We look forward to coming together with other members of the 340B community…

Read More...

Clinical Insights: January 10, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Zelsuvmi™ (berdazimer sodium) Topical Gel – New Drug Approval – January 5, 2024 – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that the U.S. Food and Drug Administration (FDA) has approved…

Read More...

Clinical Insights: January 3, 2024

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Wainua™ (eplontersen) Injection – New Orphan Drug Approval – December 21, 2023 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has approved…

Read More...

Clinical Insights: December 13, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Casgevy™ (exagamglogene autotemcel) – New Drug Approval – December 8, 2023 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced that the U.S. Food and Drug Administration…

Read More...

Our Final Podcast Episode of 2023!

RPh Innovation’s role in providing professional support services, including price file verifications and eligibility management, underscores the crucial need for strategic partnerships to optimize savings potential in the 340B landscape. In our latest 340B Insider Podcast episode, “Navigating the Complexities of 340B” RxStrategies’ Jonathan Ghenn and Rhodie Smith connect with Robert Johnson RPh, founder of…

Read More...

Clinical Insights: December 6, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage December 05, 2023 Fluorescein Sodium Injection (Resolved) December 01, 2023 Azacitidine Injection (Currently in Shortage) Hydroxypropyl Cellulose…

Read More...

Clinical Insights: November 29, 2023

Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Ogsiveo™ (nirogacestat) Tablets – New Drug Approval – November 27, 2023 – The U.S. Food and Drug Administration approved Ogsiveo™ (nirogacestat) tablets for adult patients with progressing desmoid tumors who…

Read More...